Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01580241 · ClinicalTrials.gov registry record
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
A clinical trial, sponsored by University of Oklahoma.
- Active
- Registry status
- 60
- Enrollment target
NCT01580241: Active study, sponsored by University of Oklahoma.
NCT01580241 is a clinical trial that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01580241 is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-10 |
| Est. Completion | 2027-12 |
What the registry record for NCT01580241 still lists
NCT01580241 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01580241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01580241 about?
NCT01580241 is a clinical study titled "Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer". The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
What is the current status of trial NCT01580241?
This trial is currently active not recruiting. The enrollment target is 60 participants. The study started on 2010-10. Estimated completion is 2027-12.
Who is sponsoring clinical trial NCT01580241?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia